Multiplex PCR with confronting two-pair primers for CYP1A1 Ile462Val, GSTM1, GSTT1, and NQO1 C609T

Asian Pacific Journal of Cancer Prevention

Volumn 6, Issue 3, 2005, Pages 346-352

  Kawai, Sayo ^a   Nishio, Kazuko ^a   Nakamura, Sakurako ^b   Sekido, Yoshitaka ^c   Niwa, Toshimitsu ^b   Hamajima, Nobuyuki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cytochrome P450 1A1 (CYP1A1); Glutathione S transferase M1 (GSTM1); Glutathione S transferase T1 (GSTT1); NAD(P)H:quinone oxidoreductase 1 (NQO1); Polymerase chain reaction confronting two pair primers (PCR CTPP); Polymorphisms

Indexed keywords

CYTOCHROME P450 1A1; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; NQO1 PROTEIN, HUMAN; PRIMER DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; METHODOLOGY; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOCHROME P-450 CYP1A1; DNA PRIMERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; NAD(P)H DEHYDROGENASE (QUINONE); POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT;

EID: 32944477096     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Abbas A, Delvinquiere K, Lechevrel M, et al (2004). GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma. World J Gastroenterol, 10, 3389-93.
2. Aktas D, Guney I, Alikasifoglu M, et al (2002). CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol, 86, 124-8.
3. Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Rannug A (1994). Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis, 15, 1785-90.
4. Babu KA, Reddy NG, Deendayal M, Kennedy S, Shivaji S (2004). GSTM1, GSTT1 and CYP1A1 detoxification gene polymorphisms and their relationship with advanced stages of endometriosis in South Indian women. Pharmacogenet Genomics, 15, 167-72.
5. Bailey LR, Roodi N, Verrier CS, et al (1998). Breast cancer and CYPIA1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res, 58, 65-70.
6. Bartsch H, Nair U, Risch A, et al (2000). Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev, 9, 3-28.
7. Breslauer KJ, Frank R, Blocker H, Marky LA (1986). Predicting GSTMDNA duplex stability from the base sequence. Proc Natl Acad Sci USA, 86, 3746-50.
8. Bu R, Gutierrez MI, Al-Rasheed M, Belgaumi A, Bhatia K (2004). Variable Drug metabolism genes in Arab population. Pharmacogenomics J, 4, 260-6.
9. Chen S, Xue K, Xu L, Ma G, Wu J (2001). Polymorphisms of the CYP1A1 and GSTM1 genes in relation to individual susceptibility to lung cancer carcinoma in Chinese population. Mutat Res, 458, 41-7.
10. Evans AJ, Henner WD, Eilers KM, et al (2004). Polymorphisms of GSTT1 and related genes in head and neck cancer risk. Head Neck, 26, 63-70.
11. Garte S, Gaspari L, Alexandrie A-K, et al (2001). Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev, 10, 1239-49.
12. Hamajima N (2001). PCR-CTPP: a new genotyping technique in the era of genetic epidemiology. Expert Rev Mol Diagn, 1, 119-23.
13. Hamajima N, Matsuo K, Iwata H, et al (2002a). NAD(P)H:quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8.
14. Hamajima N, Saito T, Matsuo K, Tajima K (2002b). Competitive amplification and unspecific amplification in polymerase chain reaction with confronting two-pair primers. J Mol Diagn, 4, 103-7.
15. Hirvonen A, Husgafvel-Pursiainen K, Karjalainen A, Anttila S, Vainio H (1992). Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev, 1, 485-9.
16. Hong YS, Chang JH, Kwon OJ, Ham YA, Choi JH (1998). Polymorphism of the CYP1A1 and glutathione-S-transferase gene in Korean lung cancer patients. Exp Mol Med, 30, 192-8.
17. Huang CS, Shen CY, Chang KJ, Hsu SM, Chern HD (1999). Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer, 80, 1838-43.
18. Inoue H, Kiyohara C, Marugame T, et al (2000). Cigarette smoking, CYP1A1 MspI and GSTM1 genotypes, and colorectal adenomas. Cancer Res, 60, 3749-52.
19. Joseph T, Kusumakumary P, Chacko P, Abraham A, Radhakrishna Pillai M (2004). Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer, 43, 560- 7.
20. Kawase H, Hamajima N, Tamakoshi A, et al (2003). Triplex Polymerase Chain Reaction with Confronting Two-Pair Primers (PCR-CTPP) for NQO1 C609T, GSTM1 and GSTT1 Polymorphisms: a Convenient Genotyping Method. Asian Pacific J Cancer Prev, 4, 67-70.
21. Katoh T, Nagata N, Kuroda Y, et al (1996). Glutathione Stransferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis, 17, 1855-9.
22. Kietthubthew S, Sriplung H, Au WW (2001). Genetic and environmental interactions on oral cancer in Southern Thailand. Environ Mol Mutagen, 37, 111-6.
23. Kihara M, Kihara M, Noda K (1994). Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis, 15, 415-8.
24. Kim KS, Ryu SW, Kim YJ, Kim E (1999). Polymorphism analysis of the CYP1A1 locus in Koreans: presence of the solitary m2 allele. Mol Cells, 9, 78-83.
25. Kim W-J, Lee H-L, Lee S-C, et al (2000). Polymorphisms of Nacetyltransferase 2, glutathione S-transferase Mu and Theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. J Urol, 164, 209-13.
26. Kiyohara C, Wakai K, Mikami H, et al (2003). Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese nonsmoking women. Int J Cancer, 107, 139- 44.
27. Lafuente MJ, Casterad X, Trias M, et al (2000). NAD(P)H:quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis, 21, 1813-19.
28. Larson RA, Wang Y, Banerjee M, et al (1999). Prevalence of the inactivating 609C_T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94, 803-7.
29. Lin P, Wang H-J, Lee H, et al (1999). NAD(P)H: quinone oxidoreductase polymorphism and lung cancer in Taiwan. J Toxicol Environ Health, Part A, 58, 187-97.
30. Murata M, Watanabe M, Yamanaka M, et al (2001). Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett, 165, 171-7.
31. Naoe T, Takeyama K, Yokozawa T, et al (2000). Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res, 6, 4091-5.
32. Nishio K, Tanaka D, Atsuta Y, et al (2004). Genotype announcement in a genetic polymorphism study for health checkup examinees at Nagoya university hospital. Nagoya J Med Sci, 67, 45-9.
33. Oyama T, Kawamoto T, Mizoue T, et al (1997). P53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int J Oncol, 11, 305-9.
34. Pae CU, Yu HS, Kim JJ, et al (2004). Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmacol, 7, 495-500.
35. Park S-K, Yoo K-Y, Lee S-J, et al (2000). Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. Pharmacogenetics, 10: 301-9.
36. Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH (1995). Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199-206.
37. Schulz WA, Krummeck A, Rosinger I, et al (1997). Increased frequency of a null-allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7, 235-9.
38. Setiawan VW, Zhang Z-F, Yu G-P, et al (2001a). GSTT1 and GSTM1 null genotypes and the risk of gastric cancer: a casecontrol study in a Chinese population. Cancer Epidemiol Biomarkers Prev, 9, 73-80.
39. Siegel D, McGuinness SM, Winski SL, Ross D (1999). Genotypephenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9, 113-21.
40. Sikdar N, Mahmud SA, Paul RR, Roy B (2003). Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users. Cancer Lett, 195, 33-42.
41. Slattery ML, Potter JD, Samowitz W, et al (1998). NAT2, GSTMDNA 1, cigarette smoking, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev, 7, 1079-84.
42. Smith MT, Wang Y, Kane E, et al (2001). Low NAD(P)H:quinone oxidoreductase 1 activity is associated with incrased risk of acute leukemia in adults. Blood, 97, 1422-6.
43. Smith MT, Wang Y, Skibola CF, et al (2002). Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood, 100, 4590-3.
44. Sobti RC, Sharma S, Joshi A Jindal SK, Janmeja A (2004). Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north Indian population. Mol Cell Biochem, 266, 1-9.
45. Song C, Tan W, Xing D, Lin D (2001a). CYP1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a casecontrol study in China. Carcinogenesis, 22, 11-6.
46. Wiemels JL, Pagnamenta A, Taylor GM, et al (1999). A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res, 59, 4095-9.
47. Wang LI, Giovannucci EL, Hunter D, et al (2004). Dietary intake of Cruciferous vegetables, Glutathione S-transferase (GST) polymorphisms and lung cancer risk in a Caucasian population. Cancer Causes Control, 15, 977-85.
48. Wong R-H, Du C-L Wang J-D, et al (2002). XRCC1 and CYP2E1 polymorphisms as susceptibility factors of plasma mutant p53 protein and anti-p53 antibody expression in vinyl chloride monomer-exposed polyvinyl chloride workers. Cancer Epidemiol Biomarkers Prev, 11, 475-82.
49. Xu LL, Wain JC, Miller DP, et al (2001). The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev, 10, 303-9.
50. Yoshimura K, Hanaoka T, Ohnami S, et al (2003). Allele frequencies of single nucleotide polymorphisms (SNPs) in 40 candidate genes for gene-environment studies on cancer: data from population-based Japanese random samples. J Hum Genet, 48, 654-8.
51. Zhang J, Schulz WA, Li Y, et al (2003). Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis, 24, 905- 9.
52. Zhao B, Seow A, Lee EJ, et al (2001). Dietary isothiocyanates, glutathione S-transferase-M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev, 10, 1063-7.